Replies to post #240474 on Biotech Values

[dewophile]

Enta doesn’t need the money at all so I see no reason to monetize the royalty.
Even if you saw eye to eye on future sales with one of the royalty companies you are always going to give up some discount when calculating NPV so unless you think you can earn a rate of return on the money that is greater than this discount it doesn’t make sense to monetize.